by applying the latest science, technology and research, guardion health sciences (ghs) has positioned itself to address the escalating demand for solutions that promise to improve life-diminishing health problems facing the aging baby boomer generation. guardion health sciences is dedicated to applying a scientific discipline and pharmaceutical approach to the development of safe, standardized and effective condition specific solutions. using the individual and collective knowledge of the members of our science advisory board, we will advise healthcare professionals and the public on the importance of medical foods and nutrition to achieve overall good health. the company’s first medical food, lumega-z, is scientifically formulated to restore and maintain the macular protective pigment. a depleted macular pigment is a known contributor to amd. though lumega-z was created with the amd epidemic in mind, its ingredients are also thought to be beneficial for other types of eye disease (i.
![Guardion Health Sciences logo](/files/LOGO/1642375-GHSI.png)
Company profile
Ticker
GHSI
Exchange
Website
CEO
David W. Evans
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Guardion Health Sciences, LLC
SEC CIK
Corporate docs
Subsidiaries
VectorVision Ocular Health, Inc. • Transcranial Doppler Solutions, Inc. • NutriGuard Formulations, Inc. • Viactiv Nutrititionals, Inc. ...
IRS number
474428421
GHSI stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
15 Jul 24
8-K
Entry into a Material Definitive Agreement
6 Jun 24
DEFA14A
Additional proxy soliciting materials
23 May 24
8-K
Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business
23 May 24
8-K
Other Events
21 May 24
DEFA14A
Additional proxy soliciting materials
21 May 24
DEFA14A
Additional proxy soliciting materials
15 May 24
8-K
Guardion Health Sciences Announces Board of Directors Urges Stockholders to Vote to Approve the Sale of the Company’s Viactiv Brand and Business and Plan of Liquidation and Dissolution
15 May 24
10-Q
2024 Q1
Quarterly report
13 May 24
424B5
Prospectus supplement for primary offering
6 May 24
Transcripts
Latest ownership filings
3
Initial statement of insider ownership
3 Apr 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
SC 13G/A
Hudson Bay Capital Management LP
5 Feb 24
3
Katharine Joan Cox
7 Aug 23
4
ROBERT N WEINGARTEN
5 Jul 23
4
Donald A Gagliano
5 Jul 23
4
Michaela Griggs
5 Jul 23
4
Mark Goldstone
5 Jul 23
4
Janet Hall
31 May 23
3
Janet Hall
31 May 23
Financial summary
Quarter (USD) | Mar 24 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.61 mm | 5.61 mm | 5.61 mm | 5.61 mm | 5.61 mm | 5.61 mm |
Cash burn (monthly) | 684.09 k | 858.37 k | 517.93 k | 400.28 k | 251.54 k | 317.24 k |
Cash used (since last report) | 2.64 mm | 3.32 mm | 2.00 mm | 1.55 mm | 972.41 k | 1.23 mm |
Cash remaining | 2.96 mm | 2.29 mm | 3.60 mm | 4.06 mm | 4.63 mm | 4.38 mm |
Runway (months of cash) | 4.3 | 2.7 | 7.0 | 10.1 | 18.4 | 13.8 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 174.00 k |
Total shares | 5.03 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 5.00 mm | $0.00 |
Radoff Bradley Louis | 25.10 k | $174.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 May 23 | Janet Hall | Stock option Common Stock | Grant | Acquire A | No | No | 6.01 | 10,000 | 60.10 k | 10,000 |
News
Guardion Health Sciences' Largest Stockholder Has Voted In Favor Of Proposals To Sell The Viactiv Business And The Liquidation Plan At The Company's Special Meeting Of Stockholders On May 23, 2024
21 May 24
Guardion Health Sciences Q1 EPS $(3.71) Misses $(0.88) Estimate, Sales $3.00M Miss $3.12M Estimate
13 May 24
Press releases
Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor's Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution
31 May 24
Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business
23 May 24
Guardion Health Sciences Announces
13 May 24